Abstract
Chronic inflammation is important in the development of benign prostatic hyperplasia (BPH) and certain oral antidiabetic medications have anti-inflammatory properties. The purpose of this study was to determine if use of thiazolidinediones or metformin was associated with a reduced risk of requiring medical or surgical treatment for BPH compared to sulfonylureas among diabetic men. We constructed a retrospective cohort of 192,457 male veterans newly prescribed either rosiglitazone, pioglitazone, metformin, or a sulfonylurea. We used Cox proportional hazard regression to assess the association between thiazolidinedione or metformin use and the risk of requiring medical or surgical treatment for BPH compared to sulfonylurea use. New BPH treatment was defined by either a new prescription for a α-1 blocker or 5α-reductase inhibitors or a surgical procedure indicated for severe BPH. In 259,995 person-years of follow up we identified 14,690 new treatments for BPH. After adjusting for covariates including age, HbA1c, and body mass index, we found no association between rosiglitazone (adjusted hazard ratio [aHR] 1.02, 95% CI 0.86, 1.20), pioglitazone (aHR 0.79, 95% CI 0.45, 1.38), or metformin use (aHR 0.99, 95% CI 0.94, 1.03) and risk...Continue Reading
References
Feb 14, 1998·Nature·J Jiang, G Struhl
Feb 5, 2003·European Urology·Franco Di SilverioAlessandro Sciarra
Apr 2, 2004·Nature Medicine·Ronald M EvansYong-Xu Wang
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Sep 25, 2004·The Prostate·Sabine RohrmannElizabeth A Platz
Oct 14, 2005·Proceedings of the American Thoracic Society·Theodore J StandifordRaju C Reddy
Aug 15, 2006·European Urology·Giuseppe PennaLuciano Adorini
Aug 15, 2006·American Journal of Epidemiology·Jennifer L St SauverSteven J Jacobsen
May 17, 2007·The Journal of Clinical Endocrinology and Metabolism·Yuri TakemuraYuji Taketani
Aug 14, 2008·American Journal of Epidemiology·Teemu J MurtolaAnssi Auvinen
Mar 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giuseppe PennaLuciano Adorini
Jun 11, 2009·International Journal of Andrology·B FibbiM Maggi
Aug 5, 2009·Cancer Causes & Control : CCC·Jonathan L Wright, Janet L Stanford
Oct 1, 2009·The Prostate·A VikramP Ramarao
Oct 17, 2009·Cell Death and Differentiation·M JiangS W Hayward
Feb 10, 2010·American Journal of Epidemiology·Jeannette M SchenkIan M Thompson
May 6, 2010·Molecular Cancer Therapeutics·Issam Ben SahraFrédéric Bost
Aug 24, 2010·British Journal of Pharmacology·Ajit VikramPoduri Ramarao
Oct 16, 2010·Cancer Prevention Research·Andrea DecensiSara Gandini
Feb 15, 2011·Reproductive Biomedicine Online·Ariane GermeyerThomas Strowitzki
Jun 8, 2011·Differentiation; Research in Biological Diversity·Ming JiangSimon W Hayward
Jan 4, 2012·Diabetes Care·UNKNOWN American Diabetes Association
Jan 20, 2012·Kidney International·Adriana M HungMarie R Griffin
Mar 21, 2012·BJU International·Siobhan SutcliffeUNKNOWN Urologic Diseases in America Project
Nov 7, 2012·Annals of Internal Medicine·Christianne L RoumieMarie R Griffin
Citations
Apr 19, 2016·Andrology·S La VigneraA E Calogero
Nov 10, 2017·American Journal of Physiology. Renal Physiology·Zongwei Wang, Aria F Olumi
Mar 31, 2016·Cancer Prevention Research·Chen-Pin WangAmelie G Ramirez
Dec 30, 2020·BMJ Open·Mette NørgaardReimar Wernich Thomsen
Jan 29, 2021·International Neurourology Journal·Min Ho LeeSung Chul Kam
Apr 9, 2021·The World Journal of Men's Health·Chin Hsiao Tseng